{"id":"nucleos-t-ide-analogue-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Hepatomegaly"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs are nucleotide or nucleoside mimics that incorporate into the growing viral DNA chain during replication, causing chain termination and blocking further synthesis. They are commonly used in chronic viral infections such as hepatitis B and HIV, where they suppress viral load by preventing the virus from copying its genetic material.","oneSentence":"Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase, preventing viral DNA synthesis and replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:57:54.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"HIV infection"}]},"trialDetails":[{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":"Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative","enrollment":15},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":"Hepatitis B, Chronic","enrollment":700},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":"Chronic Hepatitis b, Hepatitis B Reactivation","enrollment":260},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":"Hepatitis B, Chronic","enrollment":174},{"nctId":"NCT05630807","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-07","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":981},{"nctId":"NCT05630820","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-06","conditions":"Chronic Hepatitis B, Hepatitis B, Chronic","enrollment":857},{"nctId":"NCT06550128","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2024-07-10","conditions":"Hepatitis B, Chronic","enrollment":86},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT04980482","phase":"PHASE2","title":"Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-10-29","conditions":"Chronic Hepatitis b","enrollment":43},{"nctId":"NCT07179575","phase":"PHASE1, PHASE2","title":"Study of LW231 in Participants With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2025-10","conditions":"Chronic HBV Infection","enrollment":270},{"nctId":"NCT06829329","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2024-12-13","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT05330455","phase":"PHASE1, PHASE2","title":"Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-04-14","conditions":"Hepatitis B","enrollment":74},{"nctId":"NCT07095855","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhimeng Biopharma, Inc.","startDate":"2025-08","conditions":"Chronic Hepatitis B","enrollment":1300},{"nctId":"NCT06537414","phase":"PHASE2","title":"A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"Chronic Hepatitis B Virus Infection, Hepatitis B","enrollment":283},{"nctId":"NCT05960240","phase":"PHASE1","title":"Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arbutus Biopharma Corporation","startDate":"2023-08-30","conditions":"Chronic Hepatitis b","enrollment":128},{"nctId":"NCT06885710","phase":"PHASE1","title":"HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-12-31","conditions":"Chronic Hepatitis b","enrollment":19},{"nctId":"NCT04102176","phase":"NA","title":"Halting Nucleoside Analogues in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seng Gee Lim","startDate":"2019-01-29","conditions":"Chronic Hepatitis B","enrollment":120},{"nctId":"NCT05550519","phase":"EARLY_PHASE1","title":"A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment","status":"WITHDRAWN","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2022-10-31","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT04439539","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-14","conditions":"Hepatitis B, Chronic","enrollment":54},{"nctId":"NCT05123599","phase":"PHASE1","title":"A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-06","conditions":"Hepatitis B, Chronic","enrollment":24},{"nctId":"NCT04585789","phase":"PHASE2","title":"A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-11","conditions":"Hepatitis B","enrollment":24},{"nctId":"NCT05182463","phase":"PHASE4","title":"Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-01-08","conditions":"Hepatitis B, Chronic","enrollment":5000},{"nctId":"NCT04535544","phase":"PHASE2","title":"A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hepatitis D, Chronic","enrollment":52},{"nctId":"NCT05275023","phase":"PHASE2","title":"An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-06-30","conditions":"Hepatitis B, Chronic","enrollment":37},{"nctId":"NCT04035837","phase":"PHASE4","title":"The Clinical Cure Project of Chronic Hepatitis B in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-05-16","conditions":"Hepatitis B, Chronic","enrollment":30000},{"nctId":"NCT04954859","phase":"PHASE2","title":"Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-12-14","conditions":"Hepatitis B","enrollment":450},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT06263959","phase":"PHASE2","title":"A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Evaluate the Safety and Efficacy of GST-HG131 Tablets in Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2023-12-26","conditions":"Chronic Hepatitis B","enrollment":45},{"nctId":"NCT04129554","phase":"PHASE2","title":"A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-11-06","conditions":"Hepatitis B, Chronic","enrollment":130},{"nctId":"NCT03982186","phase":"PHASE2","title":"A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2019-08-01","conditions":"Hepatitis B, Chronic","enrollment":471},{"nctId":"NCT05423106","phase":"PHASE1","title":"A Single and Multiple Ascending Dose Study of JNJ-64457744","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-04","conditions":"Healthy, Hepatitis B, Chronic","enrollment":60},{"nctId":"NCT02883647","phase":"","title":"Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2014-01-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT06245291","phase":"PHASE2","title":"Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection","status":"WITHDRAWN","sponsor":"Arbutus Biopharma Corporation","startDate":"2024-05-01","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT04667104","phase":"PHASE2","title":"A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hepatitis B, Chronic","enrollment":48},{"nctId":"NCT04779970","phase":"NA","title":"COIN-B: COntrolled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2021-07-28","conditions":"Chronic Hepatitis B","enrollment":156},{"nctId":"NCT04676724","phase":"PHASE2","title":"Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-28","conditions":"Hepatitis B","enrollment":108},{"nctId":"NCT06323681","phase":"NA","title":"Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2024-02-04","conditions":"Chronic Hepatitis b","enrollment":2016},{"nctId":"NCT05005507","phase":"PHASE2","title":"A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-03","conditions":"Hepatitis B, Chronic","enrollment":1},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT05937178","phase":"","title":"Real-world Study Optimizing Nucleotide-analogues","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2023-01-31","conditions":"Hepatitis B, Chronic","enrollment":20000},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT05905731","phase":"PHASE1","title":"Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2023-06-01","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT05671315","phase":"NA","title":"A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients","status":"RECRUITING","sponsor":"Qing XIe","startDate":"2019-07-03","conditions":"Chronic Hepatitis B, Intermediate to High Risk of HCC","enrollment":267},{"nctId":"NCT05793268","phase":"NA","title":"Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"E-DA Hospital","startDate":"2022-12-20","conditions":"Chronic Hepatitis b","enrollment":360},{"nctId":"NCT05494528","phase":"NA","title":"Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-05-04","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT04775797","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection","status":"TERMINATED","sponsor":"Arbutus Biopharma Corporation","startDate":"2021-06-25","conditions":"Chronic Hepatitis","enrollment":110},{"nctId":"NCT03361956","phase":"PHASE2","title":"An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-02-13","conditions":"Hepatitis B","enrollment":232},{"nctId":"NCT05256823","phase":"PHASE2","title":"Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues on the Hepatitis B Surface Antigen of Virally Suppressed Subjects With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Lai Wei","startDate":"2022-02-24","conditions":"To Evaluate the Safety and Efficacy of Celecoxib Plus Nucleos(t)Ide Analogues in Nucleos(t)Ide-treated Patients With Chronic Hepatitis B","enrollment":47},{"nctId":"NCT04199819","phase":"NA","title":"Detecting Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-01-01","conditions":"Occult Hepatitis B, Liver Transplant; Complications","enrollment":100},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT03463369","phase":"PHASE1","title":"A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2018-04-18","conditions":"Hepatitis B, Chronic","enrollment":30},{"nctId":"NCT02582333","phase":"","title":"Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2015-10-01","conditions":"Virological Breakthrough, Prognosis","enrollment":347},{"nctId":"NCT03909191","phase":"","title":"Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2016-02-01","conditions":"Chronic HBV Infection, Drug Withdrawal","enrollment":454},{"nctId":"NCT03258710","phase":"PHASE4","title":"A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-02","conditions":"Hepatitis B, Chronic","enrollment":75},{"nctId":"NCT01726439","phase":"","title":"Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-12","conditions":"Chronic Hepatitis B","enrollment":3434},{"nctId":"NCT03957629","phase":"NA","title":"Optimized Treatment of Peginterferon Alfa 2a in Treatment Experienced Patients With HBV Related Liver Fibrosis","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2019-11-06","conditions":"Hepatitis B, Liver Fibrosis","enrollment":186},{"nctId":"NCT01373684","phase":"PHASE4","title":"PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-05-25","conditions":"Chronic Hepatitis B","enrollment":90},{"nctId":"NCT02431312","phase":"PHASE1","title":"Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects","status":"COMPLETED","sponsor":"Inovio Pharmaceuticals","startDate":"2015-01-12","conditions":"Hepatitis B","enrollment":90},{"nctId":"NCT01928511","phase":"PHASE4","title":"Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy","status":"COMPLETED","sponsor":"Seng Gee Lim","startDate":"2014-01","conditions":"Chronic Hepatitis B","enrollment":254},{"nctId":"NCT02364336","phase":"PHASE2","title":"Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2015-02-14","conditions":"Chronic Hepatitis B","enrollment":14},{"nctId":"NCT03977987","phase":"","title":"Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2011-01-01","conditions":"Hepatitis B","enrollment":233},{"nctId":"NCT03643172","phase":"","title":"Terminator 2 Register","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2018-09-01","conditions":"Chronic Hepatitis B, HBeAg Negative","enrollment":50},{"nctId":"NCT01532843","phase":"PHASE4","title":"Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2012-06","conditions":"Chronic Hepatitis B","enrollment":82},{"nctId":"NCT02631096","phase":"PHASE2","title":"Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy","status":"COMPLETED","sponsor":"Arbutus Biopharma Corporation","startDate":"2015-12","conditions":"Hepatitis B, Chronic","enrollment":36},{"nctId":"NCT03350074","phase":"","title":"HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2013-11-05","conditions":"Hepatitis B, Chronic","enrollment":19},{"nctId":"NCT01855997","phase":"","title":"A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-20","conditions":"Hepatitis B, Chronic","enrollment":1669},{"nctId":"NCT01706575","phase":"PHASE2","title":"A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-01","conditions":"Hepatitis B, Chronic","enrollment":76},{"nctId":"NCT02249988","phase":"PHASE2, PHASE3","title":"Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2014-12","conditions":"Chronic Hepatitis B","enrollment":261},{"nctId":"NCT02973646","phase":"PHASE4","title":"Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2016-01","conditions":"Chronic Hepatitis b","enrollment":100},{"nctId":"NCT00883844","phase":"PHASE4","title":"PEG-IFN in HBV Patients With Incomplete Response to NA","status":"COMPLETED","sponsor":"Foundation for Liver Research","startDate":"2009-04","conditions":"Chronic Hepatitis B","enrollment":11},{"nctId":"NCT01533051","phase":"","title":"Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis B","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-02","conditions":"Chronic Hepatitis B","enrollment":100},{"nctId":"NCT01437241","phase":"","title":"Etravirine Plus 2 Analogs in HIV-infected Patients","status":"COMPLETED","sponsor":"Hospitales Universitarios Virgen del Rocío","startDate":"2009-01","conditions":"HIV-1-infection","enrollment":175}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["includes lamivudine, adefovir, entecavir, tenofovir or combinations thereof"],"phase":"marketed","status":"active","brandName":"Nucleos(t)ide analogue therapy","genericName":"Nucleos(t)ide analogue therapy","companyName":"Seng Gee Lim","companyId":"seng-gee-lim","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nucleos(t)ide analogues inhibit viral reverse transcriptase and/or polymerase, preventing viral replication by blocking the synthesis of viral nucleic acids. Used for HIV-1 infection (as part of combination antiretroviral therapy), Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}